Exogene is a biotechnology startup accelerating the discovery of T-cell-receptor- (TCR-) based cell therapies for otherwise untreatable solid tumours. They are building a machine learning platform to comprehensively screen TCRs from tumour-infiltrating lymphocytes (TILs) derived from cancer patients to rapidly find new cancer targets and target-specific TCRs for therapeutic application. Using novel wet-lab TCR-screening technologies (yeast display combined with mammalian display), Exogene is able to generate data for their machine learning platform in-house by screening billions of TCR-target interactions.